Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing since 12/18/2024, newest first.
| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
City Therapeutics, Inc.
13G
178782108
|
7.0% |
10/26/2026
Event 10/19/2026
|
|||
| Viking Global Investors LP | 7.0% | ||||
| Viking Global Opportunities Parent GP LLC | 7.0% | ||||
| Viking Global Opportunities GP LLC | 4.9% | ||||
| Viking Global Opportunities Portfolio GP LLC | 4.9% | ||||
| Viking Global Opportunities Illiquid Investments Sub-Master LP | 4.9% | ||||
| Viking Global Opportunities Vintage IV GP LLC | 2.1% | ||||
| Viking Global Opportunities Vintage IV Portfolio GP LLC | 2.1% | ||||
| Viking Global Opportunities Vintage IV (Aggregator) LP | 2.1% | ||||
| Halvorsen Ole Andreas | 7.0% | ||||
| Shabet Rose Sharon | 7.0% | ||||
|
Mid America Apartment Communities Inc.
13G
MAA · 59522J103
|
5.1% |
10/5/2026
Event 9/28/2026
|
|||
| Viking Global Investors LP | 5.1% | ||||
| Viking Global Performance LLC | 3.3% | ||||
| Viking Global Equities II LP | 0.1% | ||||
| Viking Global Equities Master Ltd. | 3.2% | ||||
| Viking Long Fund GP LLC | 1.2% | ||||
| Viking Long Fund Master Ltd. | 1.2% | ||||
| Viking Global Opportunities Parent GP LLC | 0.6% | ||||
| Viking Global Opportunities GP LLC | 0.6% | ||||
| Viking Global Opportunities Portfolio GP LLC | 0.6% | ||||
| Viking Global Opportunities Liquid Portfolio Sub-Master LP | 0.6% | ||||
| Halvorsen Ole Andreas | 5.1% | ||||
| Shabet Rose Sharon | 5.1% | ||||
|
Regal Rexnord Corp
13G
RRX · 758750103
|
5.4% |
9/16/2026
Event 9/9/2026
|
|||
| Viking Global Investors LP | 5.4% | ||||
| Viking Global Performance LLC | 3.4% | ||||
| Viking Global Equities II LP | 0.1% | ||||
| Viking Global Equities Master Ltd. | 3.3% | ||||
| Viking Long Fund GP LLC | 1.3% | ||||
| Viking Long Fund Master Ltd. | 1.3% | ||||
| Viking Global Opportunities Parent GP LLC | 0.7% | ||||
| Viking Global Opportunities GP LLC | 0.7% | ||||
| Viking Global Opportunities Portfolio GP LLC | 0.7% | ||||
| Viking Global Opportunities Liquid Portfolio Sub-Master LP | 0.7% | ||||
| Halvorsen Ole Andreas | 5.4% | ||||
| Shabet Rose Sharon | 5.4% | ||||
|
Inhibrx Biosciences, Inc.
13G/A
Amendment 3
INBX · 45720N103
|
9.3% |
8/14/2026
Event 6/30/2026
|
|||
| Viking Global Investors LP | 9.3% | ||||
| Viking Global Opportunities Parent GP LLC | 9.3% | ||||
| Viking Global Opportunities GP LLC | 8.7% | ||||
| Viking Global Opportunities Portfolio GP LLC | 8.4% | ||||
| Viking Global Opportunities Illiquid Investments Sub-Master LP | 8.4% | ||||
| Kavra 104 LLC | 0.4% | ||||
| Viking Global Opportunities Drawdown GP LLC | 0.5% | ||||
| Viking Global Opportunities Drawdown Portfolio GP LLC | 0.5% | ||||
| Viking Global Opportunities Drawdown (Aggregator) LP | 0.5% | ||||
| Halvorsen Ole Andreas | 9.3% | ||||
| Shabet Rose Sharon | 9.3% | ||||
|
Oruka Therapeutics, Inc.
13G/A
Amendment 2
ORKA · 687604108
|
2.5% |
8/14/2026
Event 6/30/2026
|
|||
| Viking Global Investors LP | 2.5% | ||||
| Viking Global Opportunities Parent GP LLC | 2.5% | ||||
| Viking Global Opportunities GP LLC | 1.5% | ||||
| Viking Global Opportunities Portfolio GP LLC | 1.5% | ||||
| Viking Global Opportunities Illiquid Investments Sub-Master LP | 1.5% | ||||
| Viking Global Opportunities Drawdown GP LLC | 1.0% | ||||
| Viking Global Opportunities Drawdown Portfolio GP LLC | 1.0% | ||||
| Viking Global Opportunities Drawdown (Aggregator) LP | 1.0% | ||||
| Halvorsen Ole Andreas | 2.5% | ||||
| Shabet Rose Sharon | 2.5% | ||||
|
BridgeBio Pharma, Inc.
13D/A
Amendment 12
BBIO · 10806X102
|
5.0% |
7/10/2026
Event 7/9/2026
|
|||
| Viking Global Investors LP | 5.0% | ||||
| Viking Global Opportunities Parent GP LLC | 5.0% | ||||
| Viking Global Opportunities GP LLC | 5.0% | ||||
| Viking Global Opportunities Portfolio GP LLC | 5.0% | ||||
| Viking Global Opportunities Illiquid Investments Sub-Master LP | 5.0% | ||||
| Halvorsen Ole Andreas | 5.0% | ||||
| Shabet Rose Sharon | 5.0% | ||||
|
Standard Biotools Inc.
13D
LAB · 34385P108
|
15.0% |
6/12/2026
Event 6/6/2026
|
|||
| Viking Global Investors LP | 15.0% | ||||
| Viking Global Opportunities Parent GP LLC | 15.0% | ||||
| Viking Global Opportunities GP LLC | 10.1% | ||||
| Viking Global Opportunities Portfolio GP LLC | 10.1% | ||||
| Viking Global Opportunities Illiquid Investments Sub-Master LP | 10.1% | ||||
| Viking Global Opportunities Drawdown GP LLC | 5.0% | ||||
| Viking Global Opportunities Drawdown Portfolio GP LLC | 5.0% | ||||
| Viking Global Opportunities Drawdown (Aggregator) LP | 5.0% | ||||
| Halvorsen Ole Andreas | 15.0% | ||||
| Shabet Rose Sharon | 15.0% | ||||
|
Artiva Biotherapeutics, Inc.
13G
ARTV · 04317A107
|
5.4% |
5/18/2026
Event 5/11/2026
|
|||
| Viking Global Investors LP | 5.4% | ||||
| Viking Global Opportunities Parent GP LLC | 5.4% | ||||
| Viking Global Opportunities GP LLC | 3.8% | ||||
| Viking Global Opportunities Portfolio GP LLC | 3.8% | ||||
| Viking Global Opportunities Illiquid Investments Sub-Master LP | 3.8% | ||||
| Viking Global Opportunities Vintage IV GP LLC | 1.6% | ||||
| Viking Global Opportunities Vintage IV Portfolio GP LLC | 1.6% | ||||
| Viking Global Opportunities Vintage IV (Aggregator) LP | 1.6% | ||||
| Halvorsen Ole Andreas | 5.4% | ||||
| Shabet Rose Sharon | 5.4% | ||||
|
Inhibrx Biosciences, Inc.
13G/A
Amendment 2
INBX · 45720N103
|
10.0% |
5/15/2026
Event 3/31/2026
|
|||
| Viking Global Investors LP | 10.0% | ||||
| Viking Global Opportunities Parent GP LLC | 10.0% | ||||
| Viking Global Opportunities GP LLC | 9.3% | ||||
| Viking Global Opportunities Portfolio GP LLC | 8.8% | ||||
| Viking Global Opportunities Illiquid Investments Sub-Master LP | 8.8% | ||||
| Kavra 104 LLC | 0.5% | ||||
| Viking Global Opportunities Drawdown GP LLC | 0.7% | ||||
| Viking Global Opportunities Drawdown Portfolio GP LLC | 0.7% | ||||
| Viking Global Opportunities Drawdown (Aggregator) LP | 0.7% | ||||
| Halvorsen Ole Andreas | 10.0% | ||||
| Shabet Rose Sharon | 10.0% | ||||
|
Oruka Therapeutics, Inc.
13G/A
Amendment 1
ORKA · 687604108
|
5.3% |
5/15/2026
Event 3/31/2026
|
|||
| Viking Global Investors LP | 5.3% | ||||
| Viking Global Opportunities Parent GP LLC | 5.3% | ||||
| Viking Global Opportunities GP LLC | 3.2% | ||||
| Viking Global Opportunities Portfolio GP LLC | 3.2% | ||||
| Viking Global Opportunities Illiquid Investments Sub-Master LP | 3.2% | ||||
| Viking Global Opportunities Drawdown GP LLC | 2.1% | ||||
| Viking Global Opportunities Drawdown Portfolio GP LLC | 2.1% | ||||
| Viking Global Opportunities Drawdown (Aggregator) LP | 2.1% | ||||
| Halvorsen Ole Andreas | 5.3% | ||||
| Shabet Rose Sharon | 5.3% | ||||
|
PepGen Inc.
13G/A
Amendment 1
PEPG · 713317105
|
5.0% |
5/15/2026
Event 3/31/2026
|
|||
| Viking Global Investors LP | 5.0% | ||||
| Viking Global Opportunities Parent GP LLC | 5.0% | ||||
| Viking Global Opportunities GP LLC | 5.0% | ||||
| Viking Global Opportunities Portfolio GP LLC | 5.0% | ||||
| Viking Global Opportunities Illiquid Investments Sub-Master LP | 5.0% | ||||
| Kavra 16 LLC | 1.5% | ||||
| Halvorsen Ole Andreas | 5.0% | ||||
| Shabet Rose Sharon | 5.0% | ||||
|
Veradermics, Inc
13G/A
Amendment 1
MANE · 922967104
|
4.5% |
5/15/2026
Event 3/31/2026
|
|||
| Viking Global Investors LP | 4.5% | ||||
| Viking Global Opportunities Parent GP LLC | 4.5% | ||||
| Viking Global Opportunities GP LLC | 2.7% | ||||
| Viking Global Opportunities Portfolio GP LLC | 2.7% | ||||
| Viking Global Opportunities Illiquid Investments Sub-Master LP | 2.7% | ||||
| Viking Global Opportunities Drawdown GP LLC | 1.8% | ||||
| Viking Global Opportunities Drawdown Portfolio GP LLC | 1.8% | ||||
| Viking Global Opportunities Drawdown (Aggregator) LP | 1.8% | ||||
| Halvorsen Ole Andreas | 4.5% | ||||
| Shabet Rose Sharon | 4.5% | ||||
|
Pharvaris N.V.
13G/A
Amendment 4
PHVS · N69605108
|
5.6% |
5/15/2026
Event 3/31/2026
|
|||
| Viking Global Investors LP | 5.6% | ||||
| Viking Global Opportunities Parent GP LLC | 5.6% | ||||
| Viking Global Opportunities GP LLC | 5.6% | ||||
| Viking Global Opportunities Portfolio GP LLC | 5.6% | ||||
| Viking Global Opportunities Illiquid Investments Sub-Master LP | 5.6% | ||||
| Halvorsen Ole Andreas | 5.6% | ||||
| Shabet Rose Sharon | 5.6% | ||||
|
Adaptive Biotechnologies Corp
13G/A
Amendment 4
ADPT · 00650F109
|
18.8% |
5/15/2026
Event 3/31/2026
|
|||
| Viking Global Investors LP | 18.8% | ||||
| Viking Global Performance LLC | 13.8% | ||||
| Viking Global Equities II LP | 0.3% | ||||
| Viking Global Equities Master Ltd. | 13.5% | ||||
| Viking Long Fund GP LLC | 5.0% | ||||
| Viking Long Fund Master Ltd. | 5.0% | ||||
| Halvorsen Ole Andreas | 18.8% | ||||
| Shabet Rose Sharon | 18.8% | ||||
|
Sionna Therapeutics, Inc.
13G/A
Amendment 1
SION · 829401108
|
7.1% |
5/15/2026
Event 3/31/2026
|
|||
| Viking Global Investors LP | 7.1% | ||||
| Viking Global Opportunities Parent GP LLC | 7.1% | ||||
| Viking Global Opportunities GP LLC | 4.5% | ||||
| Viking Global Opportunities Portfolio GP LLC | 4.5% | ||||
| Viking Global Opportunities Illiquid Investments Sub-Master LP | 4.5% | ||||
| Viking Global Opportunities Drawdown GP LLC | 2.6% | ||||
| Viking Global Opportunities Drawdown Portfolio GP LLC | 2.6% | ||||
| Viking Global Opportunities Drawdown (Aggregator) LP | 2.6% | ||||
| Halvorsen Ole Andreas | 7.1% | ||||
| Shabet Rose Sharon | 7.1% | ||||
|
Oric Pharmaceuticals, Inc.
13G/A
Amendment 3
ORIC · 68622P109
|
7.8% |
5/15/2026
Event 3/31/2026
|
|||
| Viking Global Investors LP | 7.8% | ||||
| Viking Global Opportunities Parent GP LLC | 7.8% | ||||
| Viking Global Opportunities GP LLC | 5.0% | ||||
| Viking Global Opportunities Portfolio GP LLC | 5.0% | ||||
| Viking Global Opportunities Illiquid Investments Sub-Master LP | 5.0% | ||||
| Viking Global Opportunities Drawdown GP LLC | 2.8% | ||||
| Viking Global Opportunities Drawdown Portfolio GP LLC | 2.8% | ||||
| Viking Global Opportunities Drawdown (Aggregator) LP | 2.8% | ||||
| Halvorsen Ole Andreas | 7.8% | ||||
| Shabet Rose Sharon | 7.8% | ||||
|
TIC Solutions, Inc.
13G/A
Amendment 1
TIC · 00510N102
|
16.2% |
5/15/2026
Event 3/31/2026
|
|||
| Viking Global Investors LP | 16.2% | ||||
| Viking Global Opportunities Parent GP LLC | 16.2% | ||||
| Viking Global Opportunities GP LLC | 10.9% | ||||
| Viking Global Opportunities Portfolio GP LLC | 10.9% | ||||
| Viking Global Opportunities Illiquid Investments Sub-Master LP | 10.9% | ||||
| Viking Global Opportunities Drawdown GP LLC | 5.3% | ||||
| Viking Global Opportunities Drawdown Portfolio GP LLC | 5.3% | ||||
| Viking Global Opportunities Drawdown (Aggregator) LP | 5.3% | ||||
| Halvorsen Ole Andreas | 16.2% | ||||
| Shabet Rose Sharon | 16.2% | ||||
|
Standard Biotools Inc.
13G/A
Amendment 2
LAB · 34385P108
|
15.0% |
5/15/2026
Event 3/31/2026
|
|||
| Viking Global Investors LP | 15.0% | ||||
| Viking Global Opportunities Parent GP LLC | 15.0% | ||||
| Viking Global Opportunities GP LLC | 10.1% | ||||
| Viking Global Opportunities Portfolio GP LLC | 10.1% | ||||
| Viking Global Opportunities Illiquid Investments Sub-Master LP | 10.1% | ||||
| Viking Global Opportunities Drawdown GP LLC | 5.0% | ||||
| Viking Global Opportunities Drawdown Portfolio GP LLC | 5.0% | ||||
| Viking Global Opportunities Drawdown (Aggregator) LP | 5.0% | ||||
| Halvorsen Ole Andreas | 15.0% | ||||
| Shabet Rose Sharon | 15.0% | ||||
|
Fortive Corp
13G/A
Amendment 2
FTV · 34959J108
|
7.1% |
5/15/2026
Event 3/31/2026
|
|||
| Viking Global Investors LP | 7.1% | ||||
| Viking Global Performance LLC | 4.6% | ||||
| Viking Global Equities II LP | 0.1% | ||||
| Viking Global Equities Master Ltd. | 4.5% | ||||
| Viking Long Fund GP LLC | 1.6% | ||||
| Viking Long Fund Master Ltd. | 1.6% | ||||
| Viking Global Opportunities Parent GP LLC | 0.8% | ||||
| Viking Global Opportunities GP LLC | 0.8% | ||||
| Viking Global Opportunities Portfolio GP LLC | 0.8% | ||||
| Viking Global Opportunities Liquid Portfolio Sub-Master LP | 0.8% | ||||
| Halvorsen Ole Andreas | 7.1% | ||||
| Shabet Rose Sharon | 7.1% | ||||
|
Rallybio Corporation
13G/A
Amendment 4
RLYB · 75120L209
|
10.0% |
5/15/2026
Event 3/31/2026
|
|||
| Viking Global Investors LP | 10.0% | ||||
| Viking Global Opportunities Parent GP LLC | 10.0% | ||||
| Viking Global Opportunities GP LLC | 10.0% | ||||
| Viking Global Opportunities Portfolio GP LLC | 10.0% | ||||
| Viking Global Opportunities Illiquid Investments Sub-Master LP | 10.0% | ||||
| Halvorsen Ole Andreas | 10.0% | ||||
| Shabet Rose Sharon | 10.0% | ||||
|
Chewy, Inc.
13G/A
Amendment 1
CHWY · 16679L109
|
0% |
5/15/2026
Event 3/31/2026
|
|||
| Viking Global Investors LP | 0% | ||||
| Viking Global Performance LLC | 0% | ||||
| Viking Global Equities II LP | 0% | ||||
| Viking Global Equities Master Ltd. | 0% | ||||
| Viking Long Fund GP LLC | 0% | ||||
| Viking Long Fund Master Ltd. | 0% | ||||
| Viking Global Opportunities Parent GP LLC | 0% | ||||
| Viking Global Opportunities GP LLC | 0% | ||||
| Viking Global Opportunities Portfolio GP LLC | 0% | ||||
| Viking Global Opportunities Liquid Portfolio Sub-Master LP | 0% | ||||
| Halvorsen Ole Andreas | 0% | ||||
| Shabet Rose Sharon | 0% | ||||
|
Ginkgo Bioworks Holdings, Inc.
13G/A
Amendment 4
DNA · 37611X209
|
7.1% |
5/15/2026
Event 3/31/2026
|
|||
| Viking Global Investors LP | 7.1% | ||||
| Viking Global Opportunities Parent GP LLC | 7.1% | ||||
| Viking Global Opportunities GP LLC | 7.1% | ||||
| Viking Global Opportunities Portfolio GP LLC | 7.1% | ||||
| Viking Global Opportunities Illiquid Investments Sub-Master LP | 7.1% | ||||
| Halvorsen Ole Andreas | 7.1% | ||||
| Shabet Rose Sharon | 7.1% | ||||
|
Altimmune, Inc.
13G
ALT · 02155H200
|
6.7% |
5/1/2026
Event 4/24/2026
|
|||
| Viking Global Investors LP | 6.7% | ||||
| Viking Global Opportunities Parent GP LLC | 6.7% | ||||
| Viking Global Opportunities GP LLC | 4.7% | ||||
| Viking Global Opportunities Portfolio GP LLC | 4.7% | ||||
| Viking Global Opportunities Illiquid Investments Sub-Master LP | 4.7% | ||||
| Viking Global Opportunities Vintage IV GP LLC | 2.0% | ||||
| Viking Global Opportunities Vintage IV Portfolio GP LLC | 2.0% | ||||
| Viking Global Opportunities Vintage IV (Aggregator) LP | 2.0% | ||||
| Halvorsen Ole Andreas | 6.7% | ||||
| Shabet Rose Sharon | 6.7% | ||||
|
Lennox International Inc
13G
LII · 526107107
|
5.2% |
4/22/2026
Event 4/15/2026
|
|||
| Viking Global Investors LP | 5.2% | ||||
| Viking Global Performance LLC | 3.4% | ||||
| Viking Global Equities II LP | 0.1% | ||||
| Viking Global Equities Master Ltd. | 3.3% | ||||
| Viking Long Fund GP LLC | 1.2% | ||||
| Viking Long Fund Master Ltd. | 1.2% | ||||
| Viking Global Opportunities Parent GP LLC | 0.6% | ||||
| Viking Global Opportunities GP LLC | 0.6% | ||||
| Viking Global Opportunities Portfolio GP LLC | 0.6% | ||||
| Viking Global Opportunities Liquid Portfolio Sub-Master LP | 0.6% | ||||
| Halvorsen Ole Andreas | 5.2% | ||||
| Shabet Rose Sharon | 5.2% | ||||
|
BridgeBio Pharma, Inc.
13D/A
Amendment 11
BBIO · 10806X102
|
6.1% |
4/2/2026
Event 3/31/2026
|
|||
| Viking Global Investors LP | 6.1% | ||||
| Viking Global Opportunities Parent GP LLC | 6.1% | ||||
| Viking Global Opportunities GP LLC | 6.1% | ||||
| Viking Global Opportunities Portfolio GP LLC | 6.1% | ||||
| Viking Global Opportunities Illiquid Investments Sub-Master LP | 6.1% | ||||
| Halvorsen Ole Andreas | 6.1% | ||||
| Shabet Rose Sharon | 6.1% | ||||
|
BridgeBio Pharma, Inc.
13D/A
Amendment 10
BBIO · 10806X102
|
6.8% |
2/17/2026
Event 2/12/2026
|
|||
| Viking Global Investors LP | 6.8% | ||||
| Viking Global Opportunities Parent GP LLC | 6.8% | ||||
| Viking Global Opportunities GP LLC | 6.8% | ||||
| Viking Global Opportunities Portfolio GP LLC | 6.8% | ||||
| Viking Global Opportunities Illiquid Investments Sub-Master LP | 6.8% | ||||
| Halvorsen Ole Andreas | 6.8% | ||||
| Ott David C. | 6.8% | ||||
| Shabet Rose Sharon | 6.8% | ||||
|
Rallybio Corporation
13G/A
Amendment 3
RLYB · 75120L100
|
10.0% |
2/17/2026
Event 12/31/2025
|
|||
| Viking Global Investors LP | 10.0% | ||||
| Viking Global Opportunities Parent GP LLC | 10.0% | ||||
| Viking Global Opportunities GP LLC | 10.0% | ||||
| Viking Global Opportunities Portfolio GP LLC | 10.0% | ||||
| Viking Global Opportunities Illiquid Investments Sub-Master LP | 10.0% | ||||
| Halvorsen Ole Andreas | 10.0% | ||||
| Ott David C. | 10.0% | ||||
| Shabet Rose Sharon | 10.0% | ||||
|
Inhibrx Biosciences, Inc.
13G/A
Amendment 1
INBX · 45720N103
|
10.0% |
2/17/2026
Event 12/31/2025
|
|||
| Viking Global Investors LP | 10.0% | ||||
| Viking Global Opportunities Parent GP LLC | 10.0% | ||||
| Viking Global Opportunities GP LLC | 9.3% | ||||
| Viking Global Opportunities Portfolio GP LLC | 8.8% | ||||
| Viking Global Opportunities Illiquid Investments Sub-Master LP | 8.8% | ||||
| Kavra 104 LLC | 0.5% | ||||
| Viking Global Opportunities Drawdown GP LLC | 0.7% | ||||
| Viking Global Opportunities Drawdown Portfolio GP LLC | 0.7% | ||||
| Viking Global Opportunities Drawdown (Aggregator) LP | 0.7% | ||||
| Halvorsen Ole Andreas | 10.0% | ||||
| Ott David C. | 10.0% | ||||
| Shabet Rose Sharon | 10.0% | ||||
|
Primo Brands Corp
13G/A
Amendment 1
PRMB · 741623102
|
0% |
2/17/2026
Event 12/31/2025
|
|||
| Viking Global Investors LP | 0% | ||||
| Viking Global Performance LLC | 0% | ||||
| Viking Global Equities II LP | 0% | ||||
| Viking Global Equities Master Ltd. | 0% | ||||
| Viking Long Fund GP LLC | 0% | ||||
| Viking Long Fund Master Ltd. | 0% | ||||
| Viking Global Opportunities Parent GP LLC | 0% | ||||
| Viking Global Opportunities GP LLC | 0% | ||||
| Viking Global Opportunities Portfolio GP LLC | 0% | ||||
| Viking Global Opportunities Liquid Portfolio Sub-Master LP | 0% | ||||
| Halvorsen Ole Andreas | 0% | ||||
| Ott David C. | 0% | ||||
| Shabet Rose Sharon | 0% | ||||
|
Saia Inc
13G/A
Amendment 1
SAIA · 78709Y105
|
4.1% |
2/17/2026
Event 12/31/2025
|
|||
| Viking Global Investors LP | 4.1% | ||||
| Viking Global Performance LLC | 2.7% | ||||
| Viking Global Equities II LP | 0.1% | ||||
| Viking Global Equities Master Ltd. | 2.6% | ||||
| Viking Long Fund GP LLC | 1.0% | ||||
| Viking Long Fund Master Ltd. | 1.0% | ||||
| Viking Global Opportunities Parent GP LLC | 0.4% | ||||
| Viking Global Opportunities GP LLC | 0.4% | ||||
| Viking Global Opportunities Portfolio GP LLC | 0.4% | ||||
| Viking Global Opportunities Liquid Portfolio Sub-Master LP | 0.4% | ||||
| Halvorsen Ole Andreas | 4.1% | ||||
| Ott David C. | 4.1% | ||||
| Shabet Rose Sharon | 4.1% | ||||
|
NewAmsterdam Pharma Co N.V.
13G/A
Amendment 3
NAMS · N62509109
|
3.7% |
2/17/2026
Event 12/31/2025
|
|||
| Viking Global Investors LP | 3.7% | ||||
| Viking Global Opportunities Parent GP LLC | 3.7% | ||||
| Viking Global Opportunities GP LLC | 2.5% | ||||
| Viking Global Opportunities Portfolio GP LLC | 2.5% | ||||
| Viking Global Opportunities Illiquid Investments Sub-Master LP | 2.5% | ||||
| Viking Global Opportunities Drawdown GP LLC | 1.2% | ||||
| Viking Global Opportunities Drawdown Portfolio GP LLC | 1.2% | ||||
| Viking Global Opportunities Drawdown (Aggregator) LP | 1.2% | ||||
| Halvorsen Ole Andreas | 3.7% | ||||
| Ott David C. | 3.7% | ||||
| Shabet Rose Sharon | 3.7% | ||||
|
Veradermics, Inc
13G
MANE · 922967104
|
5.8% |
2/12/2026
Event 2/5/2026
|
|||
| Viking Global Investors LP | 5.8% | ||||
| Viking Global Opportunities Parent GP LLC | 5.8% | ||||
| Viking Global Opportunities GP LLC | 3.5% | ||||
| Viking Global Opportunities Portfolio GP LLC | 3.5% | ||||
| Viking Global Opportunities Illiquid Investments Sub-Master LP | 3.5% | ||||
| Viking Global Opportunities Drawdown GP LLC | 2.3% | ||||
| Viking Global Opportunities Drawdown Portfolio GP LLC | 2.3% | ||||
| Viking Global Opportunities Drawdown (Aggregator) LP | 2.3% | ||||
| Halvorsen Ole Andreas | 5.8% | ||||
| Ott David C. | 5.8% | ||||
| Shabet Rose Sharon | 5.8% | ||||
|
Regal Rexnord Corp
13G
RRX · 758750103
|
4.97% |
1/13/2026
Event 1/6/2026
|
|||
| Viking Global Investors LP | 4.97% | ||||
| Viking Global Performance LLC | 3.2% | ||||
| Viking Global Equities II LP | 0.1% | ||||
| Viking Global Equities Master Ltd. | 3.1% | ||||
| Viking Long Fund GP LLC | 1.2% | ||||
| Viking Long Fund Master Ltd. | 1.2% | ||||
| Viking Global Opportunities Parent GP LLC | 0.5% | ||||
| Viking Global Opportunities GP LLC | 0.5% | ||||
| Viking Global Opportunities Portfolio GP LLC | 0.5% | ||||
| Viking Global Opportunities Liquid Portfolio Sub-Master LP | 0.5% | ||||
| Halvorsen Ole Andreas | 4.97% | ||||
| Ott David C. | 4.97% | ||||
| Shabet Rose Sharon | 4.97% | ||||
|
Chewy, Inc.
13G
CHWY · 16679L109
|
5.7% |
12/30/2025
Event 12/18/2025
|
|||
| Viking Global Investors LP | 5.7% | ||||
| Viking Global Performance LLC | 3.7% | ||||
| Viking Global Equities II LP | 0.1% | ||||
| Viking Global Equities Master Ltd. | 3.6% | ||||
| Viking Long Fund GP LLC | 1.4% | ||||
| Viking Long Fund Master Ltd. | 1.4% | ||||
| Viking Global Opportunities Parent GP LLC | 0.6% | ||||
| Viking Global Opportunities GP LLC | 0.6% | ||||
| Viking Global Opportunities Portfolio GP LLC | 0.6% | ||||
| Viking Global Opportunities Liquid Portfolio Sub-Master LP | 0.6% | ||||
| Halvorsen Ole Andreas | 5.7% | ||||
| Ott David C. | 5.7% | ||||
| Shabet Rose Sharon | 5.7% | ||||
|
Trevi Therapeutics, Inc.
13G/A
Amendment 5
TRVI · 89532M101
|
4.2% |
11/14/2025
Event 9/30/2025
|
|||
| Viking Global Investors LP | 4.2% | ||||
| Viking Global Opportunities Parent GP LLC | 4.2% | ||||
| Viking Global Opportunities GP LLC | 2.8% | ||||
| Viking Global Opportunities Portfolio GP LLC | 2.8% | ||||
| Viking Global Opportunities Illiquid Investments Sub-Master LP | 2.8% | ||||
| Viking Global Opportunities Drawdown GP LLC | 1.4% | ||||
| Viking Global Opportunities Drawdown Portfolio GP LLC | 1.4% | ||||
| Viking Global Opportunities Drawdown (Aggregator) LP | 1.4% | ||||
| Halvorsen Ole Andreas | 4.2% | ||||
| Ott David C. | 4.2% | ||||
| Shabet Rose Sharon | 4.2% | ||||
|
Roivant Sciences Ltd.
13G/A
Amendment 6
ROIV · G76279101
|
3.4% |
11/14/2025
Event 9/30/2025
|
|||
| Viking Global Investors LP | 3.4% | ||||
| Viking Global Performance LLC | 1.8% | ||||
| Viking Global Equities II LP | <0.1% | ||||
| Viking Global Equities Master Ltd. | 1.8% | ||||
| Viking Long Fund GP LLC | 0.7% | ||||
| Viking Long Fund Master Ltd. | 0.7% | ||||
| Viking Global Opportunities Parent GP LLC | 0.9% | ||||
| Viking Global Opportunities GP LLC | 0.9% | ||||
| Viking Global Opportunities Portfolio GP LLC | 0.9% | ||||
| Viking Global Opportunities Illiquid Investments Sub-Master LP | 0.9% | ||||
| Halvorsen Ole Andreas | 3.4% | ||||
| Ott David C. | 3.4% | ||||
| Shabet Rose Sharon | 3.4% | ||||
|
Regal Rexnord Corp
13G/A
Amendment 2
RRX · 758750103
|
4.7% |
11/14/2025
Event 9/30/2025
|
|||
| Viking Global Investors LP | 4.7% | ||||
| Viking Global Performance LLC | 3.1% | ||||
| Viking Global Equities II LP | 0.1% | ||||
| Viking Global Equities Master Ltd. | 3.0% | ||||
| Viking Long Fund GP LLC | 1.2% | ||||
| Viking Long Fund Master Ltd. | 1.2% | ||||
| Viking Global Opportunities Parent GP LLC | 0.5% | ||||
| Viking Global Opportunities GP LLC | 0.5% | ||||
| Viking Global Opportunities Portfolio GP LLC | 0.5% | ||||
| Viking Global Opportunities Liquid Portfolio Sub-Master LP | 0.5% | ||||
| Halvorsen Ole Andreas | 4.7% | ||||
| Ott David C. | 4.7% | ||||
| Shabet Rose Sharon | 4.7% | ||||
|
Biomarin Pharmaceutical Inc
13G/A
Amendment 2
BMRN · 09061G101
|
4.3% |
11/14/2025
Event 9/30/2025
|
|||
| Viking Global Investors LP | 4.3% | ||||
| Viking Global Performance LLC | 2.8% | ||||
| Viking Global Equities II LP | 0.1% | ||||
| Viking Global Equities Master Ltd. | 2.8% | ||||
| Viking Long Fund GP LLC | 1.1% | ||||
| Viking Long Fund Master Ltd. | 1.1% | ||||
| Viking Global Opportunities Parent GP LLC | 0.4% | ||||
| Viking Global Opportunities GP LLC | 0.4% | ||||
| Viking Global Opportunities Portfolio GP LLC | 0.4% | ||||
| Viking Global Opportunities Liquid Portfolio Sub-Master LP | 0.4% | ||||
| Halvorsen Ole Andreas | 4.3% | ||||
| Ott David C. | 4.3% | ||||
| Shabet Rose Sharon | 4.3% | ||||
|
Fortive Corp
13G/A
Amendment 1
FTV · 34959J108
|
6.4% |
11/14/2025
Event 9/30/2025
|
|||
| Viking Global Investors LP | 6.4% | ||||
| Viking Global Performance LLC | 4.2% | ||||
| Viking Global Equities II LP | 0.1% | ||||
| Viking Global Equities Master Ltd. | 4.1% | ||||
| Viking Long Fund GP LLC | 1.6% | ||||
| Viking Long Fund Master Ltd. | 1.6% | ||||
| Viking Global Opportunities Parent GP LLC | 0.6% | ||||
| Viking Global Opportunities GP LLC | 0.6% | ||||
| Viking Global Opportunities Portfolio GP LLC | 0.6% | ||||
| Viking Global Opportunities Liquid Portfolio Sub-Master LP | 0.6% | ||||
| Halvorsen Ole Andreas | 6.4% | ||||
| Ott David C. | 6.4% | ||||
| Shabet Rose Sharon | 6.4% | ||||
|
BridgeBio Pharma, Inc.
13D/A
Amendment 9
BBIO · 10806X102
|
8.2% |
11/14/2025
Event 11/14/2025
|
|||
| Viking Global Investors LP | 8.2% | ||||
| Viking Global Performance LLC | 0% | ||||
| Viking Global Equities II LP | 0% | ||||
| Viking Global Equities Master Ltd. | 0% | ||||
| Viking Long Fund GP LLC | 0% | ||||
| Viking Long Fund Master Ltd. | 0% | ||||
| Viking Global Opportunities Parent GP LLC | 8.2% | ||||
| Viking Global Opportunities GP LLC | 8.2% | ||||
| Viking Global Opportunities Portfolio GP LLC | 8.2% | ||||
| Viking Global Opportunities Illiquid Investments Sub-Master LP | 8.2% | ||||
| Viking Global Opportunities Liquid Portfolio Sub-Master LP | 0% | ||||
| Halvorsen Ole Andreas | 8.2% | ||||
| Ott David C. | 8.2% | ||||
| Shabet Rose Sharon | 8.2% | ||||
|
PepGen Inc.
13G
PEPG · 713317105
|
5.1% |
10/3/2025
Event 9/26/2025
|
|||
| Viking Global Investors LP | 5.1% | ||||
| Viking Global Opportunities Parent GP LLC | 5.1% | ||||
| Viking Global Opportunities GP LLC | 5.1% | ||||
| Viking Global Opportunities Portfolio GP LLC | 5.1% | ||||
| Viking Global Opportunities Illiquid Investments Sub-Master LP | 5.1% | ||||
| Halvorsen Ole Andreas | 5.1% | ||||
| Ott David C. | 5.1% | ||||
| Shabet Rose Sharon | 5.1% | ||||
|
Oruka Therapeutics, Inc.
13G
ORKA · 687604108
|
5.5% |
9/24/2025
Event 9/17/2025
|
|||
| Viking Global Investors LP | 5.5% | ||||
| Viking Global Opportunities Parent GP LLC | 5.5% | ||||
| Viking Global Opportunities GP LLC | 3.3% | ||||
| Viking Global Opportunities Portfolio GP LLC | 3.3% | ||||
| Viking Global Opportunities Illiquid Investments Sub-Master LP | 3.3% | ||||
| Viking Global Opportunities Drawdown GP LLC | 2.2% | ||||
| Viking Global Opportunities Drawdown Portfolio GP LLC | 2.2% | ||||
| Viking Global Opportunities Drawdown (Aggregator) LP | 2.2% | ||||
| Halvorsen Ole Andreas | 5.5% | ||||
| Ott David C. | 5.5% | ||||
| Shabet Rose Sharon | 5.5% | ||||
|
Saia Inc
13G
SAIA · 78709Y105
|
5.0% |
9/10/2025
Event 9/3/2025
|
|||
| Viking Global Investors LP | 5.0% | ||||
| Viking Global Performance LLC | 3.3% | ||||
| Viking Global Equities II LP | 0.1% | ||||
| Viking Global Equities Master Ltd. | 3.2% | ||||
| Viking Long Fund GP LLC | 1.3% | ||||
| Viking Long Fund Master Ltd. | 1.3% | ||||
| Viking Global Opportunities Parent GP LLC | 0.5% | ||||
| Viking Global Opportunities GP LLC | 0.5% | ||||
| Viking Global Opportunities Portfolio GP LLC | 0.5% | ||||
| Viking Global Opportunities Liquid Portfolio Sub-Master LP | 0.5% | ||||
| Halvorsen Ole Andreas | 5.0% | ||||
| Ott David C. | 5.0% | ||||
| Shabet Rose Sharon | 5.0% | ||||
|
BridgeBio Pharma, Inc.
13D/A
Amendment 8
BBIO · 10806X102
|
9.7% |
8/14/2025
Event 8/14/2025
|
|||
| Viking Global Investors LP | 9.3% | ||||
| Viking Global Performance LLC | 0.1% | ||||
| Viking Global Equities II LP | 0% | ||||
| Viking Global Equities Master Ltd. | 0.1% | ||||
| Viking Long Fund GP LLC | <0.1% | ||||
| Viking Long Fund Master Ltd. | <0.1% | ||||
| Viking Global Opportunities Parent GP LLC | 9.1% | ||||
| Viking Global Opportunities GP LLC | 9.1% | ||||
| Viking Global Opportunities Portfolio GP LLC | 9.1% | ||||
| Viking Global Opportunities Illiquid Investments Sub-Master LP | 9.1% | ||||
| Viking Global Opportunities Liquid Portfolio Sub-Master LP | <0.1% | ||||
| Halvorsen Ole Andreas | 9.7% | ||||
| Ott David C. | 9.7% | ||||
| Shabet Rose Sharon | 9.7% | ||||
|
Trevi Therapeutics, Inc.
13G/A
Amendment 4
TRVI · 89532M101
|
5.9% |
8/14/2025
Event 6/30/2025
|
|||
| Viking Global Investors LP | 5.9% | ||||
| Viking Global Opportunities Parent GP LLC | 5.9% | ||||
| Viking Global Opportunities GP LLC | 3.9% | ||||
| Viking Global Opportunities Portfolio GP LLC | 3.9% | ||||
| Viking Global Opportunities Illiquid Investments Sub-Master LP | 3.9% | ||||
| Viking Global Opportunities Drawdown GP LLC | 1.9% | ||||
| Viking Global Opportunities Drawdown Portfolio GP LLC | 1.9% | ||||
| Viking Global Opportunities Drawdown (Aggregator) LP | 1.9% | ||||
| Halvorsen Ole Andreas | 5.9% | ||||
| Ott David C. | 5.9% | ||||
| Shabet Rose Sharon | 5.9% | ||||
|
APi Group Corp
13G/A
Amendment 7
APG · 00187Y100
|
2.8% |
8/14/2025
Event 6/30/2025
|
|||
| Viking Global Investors LP | 2.8% | ||||
| Viking Global Opportunities Parent GP LLC | 2.8% | ||||
| Viking Global Opportunities GP LLC | 2.8% | ||||
| Viking Global Opportunities Portfolio GP LLC | 2.8% | ||||
| Viking Global Opportunities Illiquid Investments Sub-Master LP | 2.8% | ||||
| Halvorsen Ole Andreas | 2.8% | ||||
| Ott David C. | 2.8% | ||||
| Shabet Rose Sharon | 2.8% | ||||
|
Oric Pharmaceuticals, Inc.
13G/A
Amendment 2
ORIC · 68622P109
|
10.0% |
8/14/2025
Event 6/30/2025
|
|||
| Viking Global Investors LP | 10.0% | ||||
| Viking Global Opportunities Parent GP LLC | 10.0% | ||||
| Viking Global Opportunities GP LLC | 6.4% | ||||
| Viking Global Opportunities Portfolio GP LLC | 6.4% | ||||
| Viking Global Opportunities Illiquid Investments Sub-Master LP | 6.4% | ||||
| Viking Global Opportunities Drawdown GP LLC | 3.6% | ||||
| Viking Global Opportunities Drawdown Portfolio GP LLC | 3.6% | ||||
| Viking Global Opportunities Drawdown (Aggregator) LP | 3.6% | ||||
| Halvorsen Ole Andreas | 10.0% | ||||
| Ott David C. | 10.0% | ||||
| Shabet Rose Sharon | 10.0% | ||||
|
Regal Rexnord Corp
13G/A
Amendment 1
RRX · 758750103
|
5.2% |
8/14/2025
Event 6/30/2025
|
|||
| Viking Global Investors LP | 5.2% | ||||
| Viking Global Performance LLC | 3.5% | ||||
| Viking Global Equities II LP | 0.1% | ||||
| Viking Global Equities Master Ltd. | 3.4% | ||||
| Viking Long Fund GP LLC | 1.2% | ||||
| Viking Long Fund Master Ltd. | 1.2% | ||||
| Viking Global Opportunities Parent GP LLC | 0.5% | ||||
| Viking Global Opportunities GP LLC | 0.5% | ||||
| Viking Global Opportunities Portfolio GP LLC | 0.5% | ||||
| Viking Global Opportunities Liquid Portfolio Sub-Master LP | 0.5% | ||||
| Halvorsen Ole Andreas | 5.2% | ||||
| Ott David C. | 5.2% | ||||
| Shabet Rose Sharon | 5.2% | ||||
|
Biomarin Pharmaceutical Inc
13G/A
Amendment 1
BMRN · 09061G101
|
6.4% |
8/14/2025
Event 6/30/2025
|
|||
| Viking Global Investors LP | 6.4% | ||||
| Viking Global Performance LLC | 4.3% | ||||
| Viking Global Equities II LP | 0.1% | ||||
| Viking Global Equities Master Ltd. | 4.2% | ||||
| Viking Long Fund GP LLC | 1.5% | ||||
| Viking Long Fund Master Ltd. | 1.5% | ||||
| Viking Global Opportunities Parent GP LLC | 0.6% | ||||
| Viking Global Opportunities GP LLC | 0.6% | ||||
| Viking Global Opportunities Portfolio GP LLC | 0.6% | ||||
| Viking Global Opportunities Liquid Portfolio Sub-Master LP | 0.6% | ||||
| Halvorsen Ole Andreas | 6.4% | ||||
| Ott David C. | 6.4% | ||||
| Shabet Rose Sharon | 6.4% | ||||
|
Roivant Sciences Ltd.
13G/A
Amendment 5
ROIV · G76279101
|
5.0% |
8/14/2025
Event 6/30/2025
|
|||
| Viking Global Investors LP | 5.0% | ||||
| Viking Global Performance LLC | 2.7% | ||||
| Viking Global Equities II LP | 0.1% | ||||
| Viking Global Equities Master Ltd. | 2.6% | ||||
| Viking Long Fund GP LLC | 0.9% | ||||
| Viking Long Fund Master Ltd. | 0.9% | ||||
| Viking Global Opportunities Parent GP LLC | 1.4% | ||||
| Viking Global Opportunities GP LLC | 1.4% | ||||
| Viking Global Opportunities Portfolio GP LLC | 1.4% | ||||
| Viking Global Opportunities Illiquid Investments Sub-Master LP | 1.4% | ||||
| Halvorsen Ole Andreas | 5.0% | ||||
| Ott David C. | 5.0% | ||||
| Shabet Rose Sharon | 5.0% | ||||
|
Fortive Corp
13G
FTV · 34959J108
|
5.0% |
7/24/2025
Event 7/17/2025
|
|||
| Viking Global Investors LP | 5.0% | ||||
| Viking Global Performance LLC | 3.3% | ||||
| Viking Global Equities II LP | 0.1% | ||||
| Viking Global Equities Master Ltd. | 3.3% | ||||
| Viking Long Fund GP LLC | 1.2% | ||||
| Viking Long Fund Master Ltd. | 1.2% | ||||
| Viking Global Opportunities Parent GP LLC | 0.5% | ||||
| Viking Global Opportunities GP LLC | 0.5% | ||||
| Viking Global Opportunities Portfolio GP LLC | 0.5% | ||||
| Viking Global Opportunities Liquid Portfolio Sub-Master LP | 0.5% | ||||
| Halvorsen Ole Andreas | 5.0% | ||||
| Ott David C. | 5.0% | ||||
| Shabet Rose Sharon | 5.0% | ||||
|
BridgeBio Pharma, Inc.
13D/A
Amendment 7
BBIO · 10806X102
|
9.8% |
7/1/2025
Event 6/27/2025
|
|||
| Viking Global Investors LP | 9.8% | ||||
| Viking Global Performance LLC | 0.2% | ||||
| Viking Global Equities II LP | 0% | ||||
| Viking Global Equities Master Ltd. | 0.2% | ||||
| Viking Long Fund GP LLC | 0.1% | ||||
| Viking Long Fund Master Ltd. | 0.1% | ||||
| Viking Global Opportunities Parent GP LLC | 9.6% | ||||
| Viking Global Opportunities GP LLC | 9.6% | ||||
| Viking Global Opportunities Portfolio GP LLC | 9.6% | ||||
| Viking Global Opportunities Illiquid Investments Sub-Master LP | 9.5% | ||||
| Viking Global Opportunities Liquid Portfolio Sub-Master LP | <0.1% | ||||
| Halvorsen Ole Andreas | 9.8% | ||||
| Ott David C. | 9.8% | ||||
| Shabet Rose Sharon | 9.8% | ||||
|
Primo Brands Corp
13G
PRMB · 741623102
|
5.3% |
6/18/2025
Event 6/11/2025
|
|||
| Viking Global Investors LP | 5.3% | ||||
| Viking Global Performance LLC | 3.5% | ||||
| Viking Global Equities II LP | 0.1% | ||||
| Viking Global Equities Master Ltd. | 3.4% | ||||
| Viking Long Fund GP LLC | 1.2% | ||||
| Viking Long Fund Master Ltd. | 1.2% | ||||
| Viking Global Opportunities Parent GP LLC | 0.5% | ||||
| Viking Global Opportunities GP LLC | 0.5% | ||||
| Viking Global Opportunities Portfolio GP LLC | 0.5% | ||||
| Viking Global Opportunities Liquid Portfolio Sub-Master LP | 0.5% | ||||
| Halvorsen Ole Andreas | 5.3% | ||||
| Ott David C. | 5.3% | ||||
| Shabet Rose Sharon | 5.3% | ||||
|
Roivant Sciences Ltd.
13G/A
Amendment 4
ROIV · G76279101
|
6.4% |
5/15/2025
Event 3/31/2025
|
|||
| Viking Global Investors LP | 6.4% | ||||
| Viking Global Performance LLC | 3.4% | ||||
| Viking Global Equities II LP | 0.1% | ||||
| Viking Global Equities Master Ltd. | 3.4% | ||||
| Viking Long Fund GP LLC | 1.3% | ||||
| Viking Long Fund Master Ltd. | 1.3% | ||||
| Viking Global Opportunities Parent GP LLC | 1.8% | ||||
| Viking Global Opportunities GP LLC | 1.8% | ||||
| Viking Global Opportunities Portfolio GP LLC | 1.8% | ||||
| Viking Global Opportunities Illiquid Investments Sub-Master LP | 1.8% | ||||
| Halvorsen Ole Andreas | 6.4% | ||||
| Ott David C. | 6.4% | ||||
| Shabet Rose Sharon | 6.4% | ||||
|
Oric Pharmaceuticals, Inc.
13G/A
Amendment 1
ORIC · 68622P109
|
9.2% |
5/15/2025
Event 3/31/2025
|
|||
| Viking Global Investors LP | 9.2% | ||||
| Viking Global Opportunities Parent GP LLC | 9.2% | ||||
| Viking Global Opportunities GP LLC | 6.1% | ||||
| Viking Global Opportunities Portfolio GP LLC | 6.1% | ||||
| Viking Global Opportunities Illiquid Investments Sub-Master LP | 6.1% | ||||
| Viking Global Opportunities Drawdown GP LLC | 3.2% | ||||
| Viking Global Opportunities Drawdown Portfolio GP LLC | 3.2% | ||||
| Viking Global Opportunities Drawdown (Aggregator) LP | 3.2% | ||||
| Halvorsen Ole Andreas | 9.2% | ||||
| Ott David C. | 9.2% | ||||
| Shabet Rose Sharon | 9.2% | ||||
|
Trevi Therapeutics, Inc.
13G/A
Amendment 3
TRVI · 89532M101
|
8.7% |
5/15/2025
Event 3/31/2025
|
|||
| Viking Global Investors LP | 8.7% | ||||
| Viking Global Opportunities Parent GP LLC | 8.7% | ||||
| Viking Global Opportunities GP LLC | 5.8% | ||||
| Viking Global Opportunities Portfolio GP LLC | 5.8% | ||||
| Viking Global Opportunities Illiquid Investments Sub-Master LP | 5.8% | ||||
| Viking Global Opportunities Drawdown GP LLC | 2.9% | ||||
| Viking Global Opportunities Drawdown Portfolio GP LLC | 2.9% | ||||
| Viking Global Opportunities Drawdown (Aggregator) LP | 2.9% | ||||
| Halvorsen Ole Andreas | 8.7% | ||||
| Ott David C. | 8.7% | ||||
| Shabet Rose Sharon | 8.7% | ||||
|
Acuren Corp
13G
G0093S109
|
28.3% |
5/15/2025
Event 3/31/2025
|
|||
| Viking Global Investors LP | 28.3% | ||||
| Viking Global Opportunities Parent GP LLC | 28.3% | ||||
| Viking Global Opportunities GP LLC | 19.0% | ||||
| Viking Global Opportunities Portfolio GP LLC | 19.0% | ||||
| Viking Global Opportunities Illiquid Investments Sub-Master LP | 19.0% | ||||
| Viking Global Opportunities Drawdown GP LLC | 9.3% | ||||
| Viking Global Opportunities Drawdown Portfolio GP LLC | 9.3% | ||||
| Viking Global Opportunities Drawdown (Aggregator) LP | 9.3% | ||||
| Halvorsen Ole Andreas | 28.3% | ||||
| Ott David C. | 28.3% | ||||
| Shabet Rose Sharon | 28.3% | ||||
|
Regal Rexnord Corp
13G
RRX · 758750103
|
5.3% |
4/18/2025
Event 4/11/2025
|
|||
| Viking Global Investors LP | 5.3% | ||||
| Viking Global Performance LLC | 4.0% | ||||
| Viking Global Equities II LP | 0.1% | ||||
| Viking Global Equities Master Ltd. | 3.9% | ||||
| Viking Long Fund GP LLC | 1.3% | ||||
| Viking Long Fund Master Ltd. | 1.3% | ||||
| Halvorsen Ole Andreas | 5.3% | ||||
| Ott David C. | 5.3% | ||||
| Shabet Rose Sharon | 5.3% | ||||
|
BridgeBio Pharma, Inc.
13D/A
Amendment 6
BBIO · 10806X102
|
11.7% |
3/12/2025
Event 1/31/2025
|
|||
| Viking Global Investors LP | 11.7% | ||||
| Viking Global Performance LLC | 0.3% | ||||
| Viking Global Equities Master Ltd. | 0.3% | ||||
| Viking Long Fund GP LLC | 0.1% | ||||
| Viking Long Fund Master Ltd. | 0.1% | ||||
| Viking Global Opportunities Parent GP LLC | 11.3% | ||||
| Viking Global Opportunities GP LLC | 11.3% | ||||
| Viking Global Opportunities Portfolio GP LLC | 11.3% | ||||
| Viking Global Opportunities Illiquid Investments Sub-Master LP | 11.3% | ||||
| Halvorsen Ole Andreas | 11.7% | ||||
| Ott David C. | 11.7% | ||||
| Shabet Rose Sharon | 11.7% | ||||
|
Cazoo Group Ltd
13D/A
Amendment 13
CZOOF · G2007L121
|
43.8% |
3/12/2025
Event 2/1/2024
|
|||
| Viking Global Investors LP | 43.8% | ||||
| Viking Global Performance LLC | 43.8% | ||||
| Viking Global Equities Master Ltd. | 42.9% | ||||
| Viking Global Equities II LP | 0.9% | ||||
| Halvorsen Ole Andreas | 43.8% | ||||
| Ott David C. | 43.8% | ||||
| Shabet Rose Sharon | 43.8% | ||||
|
Sionna Therapeutics, Inc.
13G
SION · 829401108
|
6.7% |
2/14/2025
Event 2/10/2025
|
|||
| Viking Global Investors LP | 6.7% | ||||
| Viking Global Opportunities Parent GP LLC | 6.7% | ||||
| Viking Global Opportunities GP LLC | 4.3% | ||||
| Viking Global Opportunities Portfolio GP LLC | 4.3% | ||||
| Viking Global Opportunities Illiquid Investments Sub-Master LP | 4.3% | ||||
| Viking Global Opportunities Drawdown GP LLC | 2.4% | ||||
| Viking Global Opportunities Drawdown Portfolio GP LLC | 2.4% | ||||
| Viking Global Opportunities Drawdown (Aggregator) LP | 2.4% | ||||
| Halvorsen Ole Andreas | 6.7% | ||||
| Ott David C. | 6.7% | ||||
| Shabet Rose Sharon | 6.7% | ||||
|
Longboard Pharmaceuticals, Inc.
13G/A
Amendment 1
LBPH · 54300N103
|
0% |
2/14/2025
Event 12/31/2024
|
|||
| Viking Global Investors LP | 0% | ||||
| Viking Global Opportunities Parent GP LLC | 0% | ||||
| Viking Global Opportunities GP LLC | 0% | ||||
| Viking Global Opportunities Portfolio GP LLC | 0% | ||||
| Viking Global Opportunities Illiquid Investments Sub-Master LP | 0% | ||||
| Halvorsen Ole Andreas | 0% | ||||
| Ott David C. | 0% | ||||
| Shabet Rose Sharon | |||||
|
NewAmsterdam Pharma Co N.V.
13G/A
Amendment 2
NAMS · N62509109
|
6.5% |
2/14/2025
Event 12/31/2024
|
|||
| Viking Global Investors LP | 6.5% | ||||
| Viking Global Opportunities Parent GP LLC | 6.5% | ||||
| Viking Global Opportunities GP LLC | 4.4% | ||||
| Viking Global Opportunities Portfolio GP LLC | 4.4% | ||||
| Viking Global Opportunities Illiquid Investments Sub-Master LP | 4.4% | ||||
| Viking Global Opportunities Drawdown GP LLC | 2.2% | ||||
| Viking Global Opportunities Drawdown Portfolio GP LLC | 2.2% | ||||
| Viking Global Opportunities Drawdown (Aggregator) LP | 2.2% | ||||
| Halvorsen Ole Andreas | 6.5% | ||||
| Ott David C. | 6.5% | ||||
| Shabet Rose Sharon | 6.5% | ||||
|
APi Group Corp
13G/A
Amendment 6
APG · 00187Y100
|
7.8% |
2/14/2025
Event 12/31/2024
|
|||
| Viking Global Investors LP | 7.8% | ||||
| Viking Global Opportunities Parent GP LLC | 7.8% | ||||
| Viking Global Opportunities GP LLC | 7.8% | ||||
| Viking Global Opportunities Portfolio GP LLC | 7.8% | ||||
| Viking Global Opportunities Illiquid Investments Sub-Master LP | 7.8% | ||||
| Halvorsen Ole Andreas | 7.8% | ||||
| Ott David C. | 7.8% | ||||
| Shabet Rose Sharon | 7.8% | ||||
|
BridgeBio Pharma, Inc.
13D/A
Amendment 5
BBIO · 10806X102
|
11.7% |
1/31/2025
Event 1/31/2025
|
|||
| Viking Global Investors LP | 11.7% | ||||
| Viking Global Performance LLC | 0.3% | ||||
| Viking Global Equities Master Ltd. | 0.3% | ||||
| Viking Long Fund GP LLC | 0.1% | ||||
| Viking Long Fund Master Ltd. | 0.1% | ||||
| Viking Global Opportunities Parent GP LLC | 11.3% | ||||
| Viking Global Opportunities GP LLC | 11.3% | ||||
| Viking Global Opportunities Portfolio GP LLC | 11.3% | ||||
| Viking Global Opportunities Illiquid Investments Sub-Master LP | 11.3% | ||||
| Halvorsen Ole Andreas | 11.7% | ||||
| Ott David C. | 11.7% | ||||
| Shabet Rose Sharon | 11.7% | ||||